- Not Just Brushing: 10 Ways to Start Caring for Baby Teeth
- USDA Proposes New Rules to Cut Sugar, Salt in School Meals
- When Schools Ask Students About Suicide, Those At Risk Get Help Sooner
- AHA News: They Married at Hospital Chapel, Days Before Groom’s Triple Bypass Surgery
- AHA News: Genes, Neighborhoods and a Surprising Finding on Stroke Risk
- Working Gets Tough When Grieving a Lost Spouse
- Pregnant Women in Rural America Often Lack Health Insurance, Upping Risks
- Do You Need an Insulin-Resistance Diet?
- Obamacare Helped Women in Some Southern States Get Better Breast Cancer Care
- Deer Carry COVID Variants No Longer Seen in People
Extended-Release Hydrocodone Painkiller Approved

FRIDAY, Oct. 25Zohydro ER (hydrocodone bitartrate extended-release) has been approved by the U.S. Food and Drug Administration for severe pain that requires round-the-clock long-term treatment, the agency said Friday in a news release.
Citing the potential for opioid abuse or dependency, even if the product is used as prescribed, the agency said the drug should be used only in cases when other painkillers have proven ineffective. The schedule II controlled substance should only be used to treat daily, chronic pain, not for as-needed pain relief, the FDA said.
The agency said it has ordered post-marketing studies of Zohydro ER to evaluate use beyond 12 weeks, and its overall potential for abuse.
The drug was evaluated in clinical studies involving more than 1,100 people with chronic pain. The most common side effects included constipation, nausea, drowsiness, headache, dizziness, dry mouth and itching.
Zohydro ER is produced by Zogenix, based in San Diego.
More information
To learn more about chronic pain, visit the U.S. National Institute of Neurological Disorders and Stroke.
Source: HealthDay
Copyright © 2023 HealthDay. All rights reserved.